Related Experiment Video
Updated: Feb 20, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Early-Stage Hodgkin Lymphoma: Time for Novel Agents?
Kishan Patel1, Alison Moskowitz1
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
None:
Combined modality therapy (cytotoxic chemotherapy followed by consolidative radiation [RT]) has historically been the standard-of-care for patients with early-stage Hodgkin lymphoma (HL). However, novel agents, such as brentuximab vedotin (BV) and immune checkpoint blockade (IO), have recently been incorporated into regimens for early-stage disease. Based on favorable outcomes in phase II clinical trials, BV- and IO-containing regimens are now National Comprehensive Cancer Network-listed options for the treatment of early-stage HL in the United States; however, further data are required to guide the optimal choice of therapy as well as the ongoing role of consolidative RT in the modern era.
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

